8-KItem 5.02 · Officer/Director ChangeItem 7.01 · Reg FD DisclosureItem 8.01 · Other EventsItem 9.01 · Financial Statements
On Feb 18, 2026 Boston Scientific's Board approved a $4.0B increase to its repurchase authorization,…
Filed with the SEC on · Summarized by InvestorsBot
On Feb 18, 2026 Boston Scientific's Board approved a $4.0B increase to its repurchase authorization, bringing the program to $5.0B total (previously $1.0B). All $5.0B remains available as of Feb 23, 2026. $BSX 📈💰 #Buyback #MedTech
Board added $4.0B to buyback capacity — no purchases announced; full $5.0B authorization is available to support EPS/dilution management going forward. Key capital-return move to watch for investors. $BSX 🔁📊 #ShareRepurchase #Healthcare